Lite Strategy (LITS) Cash from Investing Activities (2010 - 2026)
Lite Strategy (LITS) posted quarterly Cash from Investing Activities of $2.1 million for Q1 2026, up 268.72% quarter-over-quarter from $569000.0 in Q4 2025.
Lite Strategy (LITS) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Lite Strategy's Cash from Investing Activities history runs 16 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities changed N/A year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at -$97.3 million (down 277.96% YoY), while the FY2025 annual figure was $35.2 million, down 28.47% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $2.1 million, up from $569000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $24.5 million in Q4 2023, with the low at -$100.0 million in Q3 2025.
- The 5-year median for Cash from Investing Activities is $13.7 million (2022), against an average of $5.1 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities soared 196.49% in 2024, then tumbled 780.41% in 2025.
- Lite Strategy's Cash from Investing Activities stood at $10.5 million in 2022, then jumped by 132.74% to $24.5 million in 2023, then declined by 16.58% to $20.5 million in 2024, then slumped by 97.22% to $569000.0 in 2025, then jumped by 268.72% to $2.1 million in 2026.
- Business Quant data shows LITS's Cash from Investing Activities at $2.1 million in Q1 2026, $569000.0 in Q4 2025, and -$100.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | 2.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.10 Mn |
| Mar 31, 2026 | 2.10 Mn |
| Dec 31, 2025 | 569,000.00 |
| Dec 31, 2025 | 569,000.00 |
| Sep 30, 2025 | -100.00 Mn |
| Sep 30, 2025 | -100.00 Mn |
| Dec 31, 2024 | 20.45 Mn |
| Dec 31, 2024 | 20.45 Mn |
| Sep 30, 2024 | 14.70 Mn |
| Sep 30, 2024 | 14.70 Mn |
| Jun 30, 2024 | 19.54 Mn |
| Jun 30, 2024 | 19.54 Mn |
| Mar 31, 2024 | 122,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Dec 31, 2023 | 24.52 Mn |
| Dec 31, 2023 | 24.52 Mn |
| Sep 30, 2023 | 4.96 Mn |
| Sep 30, 2023 | 4.96 Mn |
| Jun 30, 2023 | 19.40 Mn |
| Jun 30, 2023 | 19.40 Mn |